GEOTHERMIA: the 1st business park in Belgium to be fuelled by geothermal energy

Published on 27 April 2017

IDEA is making zero CO2 emissions heating available to businesses who move into GEOTHERMIA, and is offering hot water at attractive prices to businesses who need it for their production processes, saving 2,600 tonnes of CO2. In 2010, IDEA, backed by almost 30 years of experience in geothermal...
Read more

Walloon biotechnology and the Japanese…

Published on 24 April 2017

Following the purchase of the Ogeda molecule by Astellas Pharma, relationships between Wallonia and Japan in the field of biotechnologies are stronger than ever. Ogeda’s relatively unknown younger sister company it4ip, based in Louvain-la-Neuve, is also increasing its Japanese partnerships,...
Read more

Ogeda acquired for 800 million euros

Published on 14 April 2017

The biotech company based in the Gosselies aeropole has been acquired this week for 800 million euros by the Japanese pharmaceutical giant Astellas. This is a record figure considering that Ogeda employs 40 people and that its revenue amounts to 1.5 million. The Japanese were seduced by the...
Read more

Clarity Pharmaceuticals is setting up in Wallonia

Published on 15 March 2017

The Australian company active in the treatment of serious illnesses is setting down roots in Liege. Clarity will be investing in the development of its company (Clarity Pharmaceuticals Europe SA) and its products in Belgium. Clarity will use its Belgian activities to expand in Europe and...
Read more

McCain invests €100 million in Lutosa (Leuze-en-Hainaut)

Published on 21 February 2017

The Canadian company McCain, the global leader in potato processing and distribution, is strengthening its presence in Belgium, the strategic heart of its European development. New investment and additional recruitment is planned for the Leuze-en-Hainaut site. Founded in Canada in 1957, McCain...
Read more

Novasep invests 27M€ in Seneffe

Published on 17 February 2017

The strategic investment supports the growing demand for development and commercial phase production of viral-vector based therapies. The new site, scheduled to be operational in early 2019, will be built at Novasep's facility in Seneffe, Belgium, to complement the existing lab-scale suites...
Read more